Comparative Pharmacology
Head-to-head clinical analysis: SIMLANDI versus SIMPONI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIMLANDI versus SIMPONI.
SIMLANDI vs SIMPONI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
Golimumab is a human monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), inhibiting its interaction with TNF receptors and thereby reducing inflammatory responses.
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
Simponi (golimumab) is administered subcutaneously. For adult rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: 50 mg once monthly. For ulcerative colitis: 200 mg subcutaneously at week 0, then 100 mg at week 2, then 100 mg every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week.
Terminal elimination half-life approximately 12-14 days (mean 12.3 days in rheumatoid arthritis patients). Supports subcutaneous dosing every 2 weeks.
Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; no significant renal or biliary elimination. Less than 0.1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor